Global X CleanTech vs Cassava Sciences Inc — how do they compare? Global X CleanTech trades at $56.22 (market cap $24.57M), while Cassava Sciences Inc trades at $0.83 (market cap $39.40M). The key difference: Cassava Sciences Inc is the larger of the two by market cap, and Global X CleanTech is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X CleanTech for 42 Days and Cassava Sciences Inc for 37 Days on average.
| CTEC | FLNA | |
|---|---|---|
Market Cap | $24.57M | $39.40M |
Volume | 1,220 | 759,018 |
Sector | Sector/Thematic | Health |
52-Week High | $78.11 | $4.64 |
52-Week Low | $50.82 | $0.68 |
Typical Hold Time | 42 Days | 37 Days |
Enterprise Value | — | -$43.28M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
CTEC invests in companies at the forefront of the clean technology industry. It focuses on disruptive innovations in renewable energy production, energy storage, smart grids, and energy efficiency, with top holdings like Enphase and First Solar.
Read more on CTEC →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →